217 related articles for article (PubMed ID: 16886626)
21. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis.
Ota T; Asamoto M; Toriyama-Baba H; Yamamoto F; Matsuoka Y; Ochiya T; Sekiya T; Terada M; Akaza H; Tsuda H
Carcinogenesis; 2000 Jul; 21(7):1391-6. PubMed ID: 10874018
[TBL] [Abstract][Full Text] [Related]
22. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Oliveira PA; Palmeira C; Lourenço LM; Lopes CA
J Exp Clin Cancer Res; 2005 Dec; 24(4):609-16. PubMed ID: 16471324
[TBL] [Abstract][Full Text] [Related]
24. Dietary beta-cryptoxanthin inhibits N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice.
Miyazawa K; Miyamoto S; Suzuki R; Yasui Y; Ikeda R; Kohno H; Yano M; Tanaka T; Hata K; Suzuki K
Oncol Rep; 2007 Feb; 17(2):297-304. PubMed ID: 17203164
[TBL] [Abstract][Full Text] [Related]
25. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
[TBL] [Abstract][Full Text] [Related]
26. [Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study].
Tong M; Yu LZ; Ding Y; Liu LB; Pan BN; Na YQ
Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):201-3. PubMed ID: 12812661
[TBL] [Abstract][Full Text] [Related]
27. Cataracts in rats given a bladder carcinogen, N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Fujita J; Yoshida O; Fujita H; Mikuni I
Tokai J Exp Clin Med; 1983 Nov; 8(4):359-63. PubMed ID: 6679940
[TBL] [Abstract][Full Text] [Related]
28. [Histological study of urinary bladder tumor: DNA of rat urinary bladder tumor caused by N-butyl-N-(4-hydroxybutyl) nitrosamine and that of human bladder tumor].
Murase T; Kobayashi O; Aota Y; Mitsuta H; Koshikawa T
Hinyokika Kiyo; 1983 Mar; 29(3):303-10. PubMed ID: 6677123
[TBL] [Abstract][Full Text] [Related]
29. A study of antitumor effects of thymosin on rat and mouse urinary bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Wada S; Kinoshita Y; Kamizuru M; Asai Y; Iwata H; Ikemoto S; Hato F; Kishimoto T; Fukushima S
Oncol Res; 1996; 8(3):139-44. PubMed ID: 8823810
[TBL] [Abstract][Full Text] [Related]
30. Effects of intravesical instillation of antitumor chemotherapeutic agents on bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Ohtani M; Fukushima S; Okamura T; Sakata T; Ito N; Koiso K; Niijima T
Cancer; 1984 Oct; 54(8):1525-9. PubMed ID: 6434176
[TBL] [Abstract][Full Text] [Related]
31. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Anticancer Res; 2009 Oct; 29(10):4201-4. PubMed ID: 19846973
[TBL] [Abstract][Full Text] [Related]
32. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
[TBL] [Abstract][Full Text] [Related]
33. [Experimental model of urinary bladder tumor in rats for evaluation of chemotherapeutic agents].
Hirao Y; Momose H; Samma S; Ozono S; Babaya K; Okajima E
Hinyokika Kiyo; 1988 Nov; 34(11):1885-93. PubMed ID: 3242363
[TBL] [Abstract][Full Text] [Related]
34. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
35. Promoting the effects of intravesical instillation of saline on bladder lesion development in rats pre-treated with BBN.
Itoh Y; Okamura T; Tozawa K; Yamada Y; Kohri K
Int J Urol; 2002 Jan; 9(1):24-8. PubMed ID: 11972646
[TBL] [Abstract][Full Text] [Related]
36. Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis.
Baffa R; Fassan M; Sevignani C; Vecchione A; Ishii H; Giarnieri E; Iozzo RV; Gomella LG; Croce CM
Carcinogenesis; 2008 Apr; 29(4):846-8. PubMed ID: 18192690
[TBL] [Abstract][Full Text] [Related]
37. Effect of intravesical instillation of antitumor drugs in the development of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumors in rats.
Suzuki T; Imai K; Takezawa Y; Tsuji H; Yamanaka H; Suzuki K
Hinyokika Kiyo; 1989 Feb; 35(2):247-51. PubMed ID: 2735235
[TBL] [Abstract][Full Text] [Related]
38. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice.
Ogawa K; St John M; Luiza de Oliveira M; Arnold L; Shirai T; Sun TT; Cohen SM
Toxicol Pathol; 1999; 27(6):645-51. PubMed ID: 10588545
[TBL] [Abstract][Full Text] [Related]
39. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis.
Iida K; Itoh K; Maher JM; Kumagai Y; Oyasu R; Mori Y; Shimazui T; Akaza H; Yamamoto M
Carcinogenesis; 2007 Nov; 28(11):2398-403. PubMed ID: 17602169
[TBL] [Abstract][Full Text] [Related]
40. A phyllodes tumor of the urinary bladder in a rat.
Oliveira PA; Colaco AA; Palmeira CA; De la Cruz P LF; Lopes CA
Exp Oncol; 2007 Jun; 29(2):159-61. PubMed ID: 17704750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
